- Lilly plans a $6 billion investment in a new API facility in Huntsville, Alabama.
- The facility will focus on small molecule synthetic and peptide medicines, including orforglipron.
- Construction begins in 2026, creating 3,000 jobs, with completion expected by 2032.
- The site will employ 450 high-value jobs and use advanced technologies for manufacturing.
Investment and Purpose
Eli Lilly and Company announced a $6 billion investment in a new manufacturing facility in Huntsville, Alabama. This facility will focus on producing small molecule synthetic and peptide medicines, including orforglipron, Lilly's oral GLP-1 receptor agonist.
Job Creation and Timeline
The project is expected to create 3,450 jobs, with 450 high-value positions in engineering, science, operations, and lab work. Construction will begin in 2026, generating 3,000 construction jobs, and is anticipated to be completed by 2032.
Strategic Location and Technology
The Huntsville site was chosen for its proximity to the HudsonAlpha Institute for Biotechnology and its access to utilities, transportation, and favorable zoning. The facility will employ state-of-the-art technologies, including machine learning, AI, and digital automation, to ensure efficient and reliable production.
Economic Impact and Supply Chain
Lilly's investment is expected to boost the local economy, with each dollar invested potentially generating up to four dollars in additional economic activity. The facility will enhance supply chain resilience and ensure reliable access to medicines in the U.S.
